iBio ($IBIO) may be a risky investment after a 10% decline in stock price, investors are now questioning their investment. Year to date iBio has risen on the upside around 420%, despite huge potential it’s looking like this investment years to come to fruition.
Earlier this year, iBio announced a partnership with Chinese partner CC-Pharming to create a coronavirus vaccine, now remember, vaccines take over 8 months to develop with an average of 10 to 15 years of public and private involvement.
Whether iBio comes up with a vaccine it will be far from now and won’t be able to actively serve the vaccine without going through the appropriate government and federal process.
In the history of vaccines, research and development typically takes around 2-5 years for the exploratory stage, then 1-2 years for clinical stage and then goes through another set of 4 to 5 phases.
What you should be investing in
While iBio is a great long term stock, there are other players developing a vaccine, one downside to iBio is that it does not develop their own vaccine but relies on partners to develop it with their plant based model therefore making iBio a manufacturer, while this may seem good it’s also risky.
Stocks I recommend for the short term are companies who are involved with coronavirus testing, right now these are the most involved companies on the front line fighting the coronavirus.
Here are some companies I recommend you look into:
- Aytu BioScience ($AYTU)
- Inovio ($INO)
- Co-Diagnostics ($CODX)
- Thermo Fisher Scientific ($TMO)
- Roche ($RHHBY)
- Quest Diagnostics ($DGX)
- Dynatronics Corporation ($DYNT)
